Thomas Helleday Ph.D.
Research Themes
Divisional Themes
- Cancer and Haematology
Group Members
- Dr Christina Bauerschmidt, Postdoc
- Daniel Ebner, Lab Manager
- Dr Esther Edlundh-Rose, Research Manager
- Dr Bastiaan Evers, Postdoc
- Dr Ponnari Gottipati, Postdoc
- Robert Latusek, DPhil Student
- Dr Cecilia Lundin, Senior Postdoc
- Guy Kingham, DPhil Student
- Diana Muftic, 2nd yr DPhil Student
- Dr Nils Nicolay, Clinical Fellow/DPhil Student
- Nicholas Pedley, DPhil Student
- Dr Eva Petermann, Postdoc
- Dr Joyce Solomons, Clinical Fellow
- Dr Navita Somaiah, Clinical Fellow/DPhil Student
- Armin Thalshammer, DPhil Student
Selected Bibliography
- Bryant Helen E, Petermann Eva, Schultz Niklas, Jemth Ann-Sofie, Loseva Olga, Issaeva Natalia, Johansson Fredrik, Fernandez Serena, McGlynn Peter, and Helleday Thomas (2009) PARP is activated at stalled forks to mediate Mre11-dependent replication restart and recombination. EMBO J, 28(17):2601-15.
- Helleday Thomas, Petermann Eva, Lundin Cecilia, Hodgson Ben, and Sharma Ricky A (2008) DNA repair pathways as targets for cancer therapy. Nat Rev Cancer, 8(3):193-204.
- Bartkova Jirina, Rezaei Nousin, Liontos Michalis, Karakaidos Panagiotis, Kletsas Dimitris, Issaeva Natalia, Vassiliou Leandros-Vassilios F, Kolettas Evangelos, Niforou Katerina, Zoumpourlis Vassilis C, Takaoka Munenori, Nakagawa Hiroshi, Tort Frederic, Fugger Kasper, Johansson Fredrik, Sehested Maxwell, Andersen Claus L, Dyrskjot Lars, Orntoft Torben, Lukas Jiri, Kittas Christos, Helleday Thomas, Halazonetis Thanos D, Bartek Jiri, and Gorgoulis Vassilis G (2006) Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints. Nature, 444(7119):633-7.
- Bryant Helen E, Schultz Niklas, Thomas Huw D, Parker Kayan M, Flower Dan, Lopez Elena, Kyle Suzanne, Meuth Mark, Curtin Nicola J, and Helleday Thomas (2005) Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature, 434(7035):913-7.
- Sorensen Claus S, Hansen Lasse T, Dziegielewski Jaroslaw, Syljuasen Randi G, Lundin Cecilia, Bartek Jiri, and Helleday Thomas (2005) The cell-cycle checkpoint kinase Chk1 is required for mammalian homologous recombination repair. Nat Cell Biol, 7(2):195-201.
| Web | Personal Website |
|---|---|
| thomas.helleday@rob.ox.ac.uk | |
| Tel | +44 (0) 1865 617324 |
Prof Thomas Helleday
The primary goal of the DNA Damage Signalling Group is to exploit tumour defects for targeted treatment of cancer. Virtually all cancers have a defect in the DNA damage response, caused by mutations in tumour suppressor genes. The defect in DNA damage signalling or repair weakens the ability of the cancer cell to properly replicate DNA, resulting in genetic instability that drives cancer progression. In this project we uncover cancer specific signalling and repair pathways, which are then targeted for novel anti-cancer treatments. The project involves identification of DNA lesions formed during replication and characterisation of DNA damage signalling and repair pathways activated by these lesions. The group is engaged in understanding basic concepts of DNA damage signalling and repair as well as conducting pre-clinical trials, to translate our basic discoveries to the clinic.
For more information on our research and a full list of publications, please visit www.helleday.org
Biography
Education
1999 Ph.D.
Stockholm University
Sweden
1996 B.Sc. in Business Administration and Economics
Stockholm University
Sweden
1995 M.Sc. in Molecular Biology
Stockholm University
Sweden
Appointments
2007 - Senior Group Leader
Radiation Oncology & Biology
University of Oxford
2006 - Professor in Molecular Genetics
Department of Genetics, Microbiology & Toxicology
Stockholm University, Sweden
2006 Professor in Cancer Genetics
Institute for Cancer Studies
University of Sheffield
2000 - 2006 Lecturer
Institute for Cancer Studies
University of Sheffield
Awards Training and Qualifications
- 2005 European Environmental Mutagen Society Young Scientist Award
- 2005 The Eppendorf-Nature Young European Investigator Award
- 2006 AstraZeneca Young Scientist Frank Rose Award, British Association for Cancer Research
- 2007 Hilda and Alfred Eriksson's Prize, The Royal Swedish Academy of Sciences
- 2007 European Assiciation for Cancer Research (EACR), Young Cancer Reaearchers Award
- 2008 Svedberg Award, SFBM and Swedish National Committee for Molecular Biosciences
- 2008 Swiss Bridge Award, Swiss Cancer League and the International Union Against Cancer (UICC)
